TY - JOUR
T1 - Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure
AU - Koitabashi, Norimichi
AU - Arai, Masashi
AU - Niwano, Kazuo
AU - Watanabe, Atai
AU - Endoh, Michiko
AU - Suguta, Masahiko
AU - Yokoyama, Tomoyuki
AU - Tada, Hiroshi
AU - Toyama, Takuji
AU - Adachi, Hitoshi
AU - Naito, Shigeto
AU - Oshima, Shigeru
AU - Nishida, Takashi
AU - Kubota, Satoshi
AU - Takigawa, Masaharu
AU - Kurabayashi, Masahiko
PY - 2008/4
Y1 - 2008/4
N2 - Background: Connective tissue growth factor (CTGF) has been recently reported as a mediator of myocardial fibrosis; however, the significance of plasma CTGF concentration has not been evaluated in patients with heart failure. The aim of this study was to investigate the clinical utility of plasma CTGF concentration for the diagnosis of heart failure. Methods and results: We evaluated fifty-two patients with chronic heart failure. The plasma concentration of CTGF and other markers of fibrosis were assessed and compared with clinical and echocardiographic data. Plasma CTGF was significantly elevated in symptomatic patients in proportion to their NYHA classes and was significantly correlated with plasma brain natriuretic peptide (BNP) concentration (r = 0.395, P < 0.01). Plasma CTGF was also correlated with plasma transforming growth factor beta (TGF-β) (r = 0.512, P < 0.01), matrix metalloproteinase (MMP)-2 (r = 0.391, P < 0.05) and tissue inhibitor of MMP (TIMP)-2 (r = 0.354, P < 0.05) concentrations. Interestingly, plasma CTGF was correlated with E/E' value evaluated by tissue Doppler echocardiography (r = 0.593, P = 0.012), but not with systolic function and left ventricular mass. Conclusion: Our study suggests that plasma CTGF concentration is a novel diagnostic marker for cardiac dysfunction and may provide additional specific information about myocardial fibrosis in chronic heart failure patients.
AB - Background: Connective tissue growth factor (CTGF) has been recently reported as a mediator of myocardial fibrosis; however, the significance of plasma CTGF concentration has not been evaluated in patients with heart failure. The aim of this study was to investigate the clinical utility of plasma CTGF concentration for the diagnosis of heart failure. Methods and results: We evaluated fifty-two patients with chronic heart failure. The plasma concentration of CTGF and other markers of fibrosis were assessed and compared with clinical and echocardiographic data. Plasma CTGF was significantly elevated in symptomatic patients in proportion to their NYHA classes and was significantly correlated with plasma brain natriuretic peptide (BNP) concentration (r = 0.395, P < 0.01). Plasma CTGF was also correlated with plasma transforming growth factor beta (TGF-β) (r = 0.512, P < 0.01), matrix metalloproteinase (MMP)-2 (r = 0.391, P < 0.05) and tissue inhibitor of MMP (TIMP)-2 (r = 0.354, P < 0.05) concentrations. Interestingly, plasma CTGF was correlated with E/E' value evaluated by tissue Doppler echocardiography (r = 0.593, P = 0.012), but not with systolic function and left ventricular mass. Conclusion: Our study suggests that plasma CTGF concentration is a novel diagnostic marker for cardiac dysfunction and may provide additional specific information about myocardial fibrosis in chronic heart failure patients.
KW - Cytokines
KW - Extracellular matrix
KW - Natriuretic peptide
KW - Ventricular remodeling
UR - http://www.scopus.com/inward/record.url?scp=41449097556&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=41449097556&partnerID=8YFLogxK
U2 - 10.1016/j.ejheart.2008.02.011
DO - 10.1016/j.ejheart.2008.02.011
M3 - Article
C2 - 18337169
AN - SCOPUS:41449097556
SN - 1388-9842
VL - 10
SP - 373
EP - 379
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
IS - 4
ER -